China's National Medical Products Administration Accepts Astellas and Pfizer's sBLA for Enfortumab Vedotin with KEYTRUDA®...
Astellas Pharma Inc. announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA® (pembrolizumab) …